Bogren Mats, Soltesz Monica, Hjorth Stephan
Division of Psychiatry, Department of Clinical Sciences, Lund University Hospital, Lund, Sweden.
Vuxenpsykiatrimottagning Psykos, Lund, Sweden.
Front Psychiatry. 2022 May 11;13:887547. doi: 10.3389/fpsyt.2022.887547. eCollection 2022.
This patient case report describes a 45-year old white unmarried man with disability pension due to schizoaffective disorder, diagnosed at the age of 24. He lives in an apartment and has housing support. Retrospectively, the patient displayed prodromal markers of a disorder within the schizophrenia spectrum many years before the onset of frank psychosis, indeed since childhood. Over the years several symptoms and signs across schizophrenia domains have been manifest: positive, negative, cognitive, and affective, among which the negative and affective symptoms and signs were the earliest to appear. While the positive, disorganized, and catatonic symptoms responded to treatment - when duly tested and complied with - the negative and affective symptoms have been notoriously difficult to handle. We now report on the successful introduction of cariprazine (CAR) to his ongoing clozapine (CLZ) medication, the result of which has been a near-complete remission of his persistent negative and psychosocial issues. We interpret this remarkable alleviation of the patient's disease - and concomitant improvement of his quality of life - in terms of neuroreceptor target complementarity between CLZ and CAR, with particular emphasis on the contributions from the D3 and D2 receptor partial agonist components of the latter agent.
本病例报告描述了一名45岁的未婚白人男子,因精神分裂症合并情感障碍领取残疾抚恤金,该病于他24岁时确诊。他住在一套公寓里,得到住房支持。回顾来看,该患者在明显精神病发作前许多年,实际上从童年起就表现出精神分裂症谱系障碍的前驱标志物。多年来,精神分裂症各领域出现了多种症状和体征:阳性、阴性、认知和情感症状,其中阴性和情感症状及体征出现最早。虽然阳性、紊乱和紧张症症状在经过适当检测并得到遵医嘱治疗时会有反应,但阴性和情感症状一直 notoriously难以处理。我们现在报告在他正在服用的氯氮平(CLZ)药物治疗中成功引入卡利拉嗪(CAR)的情况,结果是他持续存在的阴性和社会心理问题几乎完全缓解。我们根据CLZ和CAR之间的神经受体靶点互补性来解释该患者疾病的显著缓解以及随之而来的生活质量改善,特别强调后者药物的D3和D2受体部分激动剂成分的作用。